+1-888-308-5802     
Industry Categories News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With experience in technical and niche writing, he was encouraged to opt for a career in content writing and now pens down articles pertaining to market research, industry news and business trends.

He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Cipla agrees to buy U.S.-based Avenue Therapeutics in a $215m deal

Published Date: 2018-11-14         Author: Pankaj Singh

Pharmaceutical drug giant Cipla recently confirmed that its U.S.-based subsidiary, InvaGen Pharmaceuticals, Inc. has signed definitive agreements for acquiring specialty pharmaceutical company Avenue Therapeutics, also from the U.S. The deal is reported to be valued at US$ 215 million (approx. Rs 1,... Read More

IBM looks to boost scientific research using blockchain technology

Published Date: 2018-11-12         Author: Pankaj Singh

U.S. information technology giant IBM is reportedly planning to apply blockchain technology to help scientific research and to make available a record of its results. Sources with the knowledge of the matter informed that the company has recently filed a new patent application with the U.S. Patent a... Read More

Grab partners with Kasikornbank to launch mobile wallet in Thailand

Published Date: 2018-11-10         Author: Pankaj Singh

Ride-hailing company Grab recently made an announcement confirming that it has entered into a strategic partnership with Kasikornbank (KBank), the Thai lender, to bring its mobile wallet GrabPay and other related financial services into Thailand by early 2019. GrabPay, a co-branded mobile payment ap... Read More

© 2018 Fractovia. All Rights Reserved